[
  {
    "ts": null,
    "headline": "DexCom Inc. stock outperforms competitors on strong trading day",
    "summary": "DexCom Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=5fc99db04fe7695aff7a473efde66b105b84676162cb6c88e61eed0cbc1bf050",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742401800,
      "headline": "DexCom Inc. stock outperforms competitors on strong trading day",
      "id": 133282297,
      "image": "",
      "related": "DXCM",
      "source": "MarketWatch",
      "summary": "DexCom Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=5fc99db04fe7695aff7a473efde66b105b84676162cb6c88e61eed0cbc1bf050"
    }
  },
  {
    "ts": null,
    "headline": "Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next",
    "summary": "The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this.  Whatever happens, though, some stocks are still worth investing in and holding on to through market volatility.  Two excellent examples are DexCom (NASDAQ: DXCM) and Vertex Pharmaceuticals (NASDAQ: VRTX).",
    "url": "https://finnhub.io/api/news?id=989dc23fd50976f7c93b8d3b4525c25cd138e8d1acc996e1b49d20a19402920c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742392920,
      "headline": "Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next",
      "id": 133325408,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this.  Whatever happens, though, some stocks are still worth investing in and holding on to through market volatility.  Two excellent examples are DexCom (NASDAQ: DXCM) and Vertex Pharmaceuticals (NASDAQ: VRTX).",
      "url": "https://finnhub.io/api/news?id=989dc23fd50976f7c93b8d3b4525c25cd138e8d1acc996e1b49d20a19402920c"
    }
  },
  {
    "ts": null,
    "headline": "Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care",
    "summary": "EDINBURGH, Scotland & SAN DIEGO, March 19, 2025--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the \"Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East.\" The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insi",
    "url": "https://finnhub.io/api/news?id=dfa8afe56b93d52f923624a98ab0bfeeb55710e84829db01a74873bf13f494ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742371200,
      "headline": "Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care",
      "id": 133238666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "EDINBURGH, Scotland & SAN DIEGO, March 19, 2025--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the \"Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East.\" The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable insi",
      "url": "https://finnhub.io/api/news?id=dfa8afe56b93d52f923624a98ab0bfeeb55710e84829db01a74873bf13f494ed"
    }
  }
]